image
Healthcare - Biotechnology - NASDAQ - US
$ 22.23
6.4 %
$ 243 M
Market Cap
-0.77
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one CDTX stock under the worst case scenario is HIDDEN Compared to the current market price of 22.2 USD, Cidara Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one CDTX stock under the base case scenario is HIDDEN Compared to the current market price of 22.2 USD, Cidara Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one CDTX stock under the best case scenario is HIDDEN Compared to the current market price of 22.2 USD, Cidara Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CDTX

image
$28.0$28.0$26.0$26.0$24.0$24.0$22.0$22.0$20.0$20.0$18.0$18.0$16.0$16.0$14.0$14.0$12.0$12.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
1.28 M REVENUE
-98.00%
-176 M OPERATING INCOME
-619.28%
-170 M NET INCOME
-640.60%
-177 M OPERATING CASH FLOW
-686.97%
-129 K INVESTING CASH FLOW
74.46%
337 M FINANCING CASH FLOW
1197.19%
0 REVENUE
0.00%
-54.2 M OPERATING INCOME
-211.50%
-52.3 M NET INCOME
-302.86%
-29.4 M OPERATING CASH FLOW
19.84%
0 INVESTING CASH FLOW
100.00%
98.2 M FINANCING CASH FLOW
54058.79%
Balance Sheet Cidara Therapeutics, Inc.
image
Current Assets 211 M
Cash & Short-Term Investments 190 M
Receivables 1.69 M
Other Current Assets 19.2 M
Non-Current Assets 4.06 M
Long-Term Investments 0
PP&E 3.96 M
Other Non-Current Assets 96 K
88.37 %8.95 %Total Assets$214.8m
Current Liabilities 49.6 M
Accounts Payable 3.61 M
Short-Term Debt 1.64 M
Other Current Liabilities 44.3 M
Non-Current Liabilities 1.93 M
Long-Term Debt 1.93 M
Other Non-Current Liabilities 0
7.01 %3.19 %86.05 %3.76 %Total Liabilities$51.5m
EFFICIENCY
Earnings Waterfall Cidara Therapeutics, Inc.
image
Revenue 1.28 M
Cost Of Revenue 84.9 M
Gross Profit -83.6 M
Operating Expenses 92.5 M
Operating Income -176 M
Other Expenses -6.28 M
Net Income -170 M
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)1m(85m)(84m)(92m)(176m)6m(170m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
-6557.49% GROSS MARGIN
-6557.49%
-13811.92% OPERATING MARGIN
-13811.92%
-13319.76% NET MARGIN
-13319.76%
-103.99% ROE
-103.99%
-79.06% ROA
-79.06%
-105.52% ROIC
-105.52%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Cidara Therapeutics, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -170 M
Depreciation & Amortization 233 K
Capital Expenditures -129 K
Stock-Based Compensation 3.91 M
Change in Working Capital -13.9 M
Others -30.2 M
Free Cash Flow -177 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Cidara Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for CDTX of $35 , with forecasts ranging from a low of $24 to a high of $46 .
CDTX Lowest Price Target Wall Street Target
24 USD 7.96%
CDTX Average Price Target Wall Street Target
35 USD 57.44%
CDTX Highest Price Target Wall Street Target
46 USD 106.93%
Price
Max Price Target
Min Price Target
Average Price Target
505045454040353530302525202015151010Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 4
6. Ownership
Insider Ownership Cidara Therapeutics, Inc.
image
Sold
0-3 MONTHS
75.5 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
21.3 K USD 2
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
106 K USD 1
9-12 MONTHS
7. News
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors. globenewswire.com - 2 weeks ago
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that the Compensation and Human Capital Committee of its Board of Directors (Compensation Committee) granted Timothy Alefantis, a new employee, a non-qualified stock option award and restricted stock units (RSUs) for an aggregate of 27,000 shares of its common stock, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended (the Inducement Plan), with a grant date of March 31, 2025. The stock option has an exercise price of $21.54 per share, which is equal to the closing price of Cidara's common stock on the grant date. The shares subject to the option will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. All RSUs vest in four equal annual installments, with 1/4 vesting on each of the first, second, third and fourth anniversaries of the Quarterly Vesting Date (as defined below) that occurs during the calendar quarter that includes the date of grant. “Quarterly Vesting Date” means March 10, June 10, September 10 or December 10. The awards are subject to the award holder's continuous service through each vesting date and to the terms and conditions of the Inducement Plan and the standard forms of grant agreements thereunder. globenewswire.com - 1 month ago
Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that company management will participate in the 24th Annual Needham Virtual Healthcare Conference. Details are as follows: Event: 24th Annual Needham Virtual Healthcare Conference Date: Wednesday, April 9, 2025 Time: 11:00 AM ET Format: Presentation Webcast: https://wsw.com/webcast/needham146/cdtx/2261559 A replay of the presentation will be available in the Investors section on the Company's website at www.cidara.com. globenewswire.com - 1 month ago
Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics (CDTX): Here's What You Should Know The consensus price target hints at a 64.5% upside potential for Cidara Therapeutics (CDTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com - 1 month ago
Cidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and Response SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced participation in the “Other pharmaceuticals as preventive tools” panel at a World Health Organization (WHO) global meeting on H5N1 influenza preparedness and response. The meeting, titled “What research is important to prepare and respond to H5N1 influenza outbreaks,” will be held virtually on March 19, 2025, from 1:00-7:15pm Central European Time (CET)/5:00-11:15am Pacific Time (PT), and the panel discussion will take place from 6:30-7:00 pm CET/10:30-11:00am PT. globenewswire.com - 1 month ago
Cidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025 SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced two upcoming presentations at the 38th International Conference on Antiviral Research (ICAR). The conference takes place from March 17-21, 2025 in Las Vegas, Nevada. globenewswire.com - 1 month ago
Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology Data highlights potential of CD388 as a potent, universal antiviral for influenza prevention regardless of immune status globenewswire.com - 1 month ago
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided recent business updates. globenewswire.com - 1 month ago
Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer Industry veteran CFO Frank Karbe brings more than 25 years of leadership experience in the biopharma industry transitioning companies from R&D to commercialization Industry veteran CFO Frank Karbe brings more than 25 years of leadership experience in the biopharma industry transitioning companies from R&D to commercialization globenewswire.com - 2 months ago
Bullish On Cidara Therapeutics As It Doubles Down On CD388 For Universal Flu Prevention Cidara Therapeutics is leveraging its Cloudbreak platform to develop CD388 for universal influenza prophylaxis. Fortunately, they recently enrolled 5,000 subjects in its Phase 2b trial to assess CD388's safety and efficacy. CD388 inhibits viral replication and activates the immune response, and its mechanism of action actually received the FDA's Fast Track designation. seekingalpha.com - 2 months ago
Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference SAN DIEGO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the Guggenheim Securities SMID Cap Biotech Conference. globenewswire.com - 3 months ago
Cidara Therapeutics (CDTX) Just Flashed Golden Cross Signal: Do You Buy? Cidara Therapeutics, Inc. (CDTX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, CDTX's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross. zacks.com - 4 months ago
8. Profile Summary

Cidara Therapeutics, Inc. CDTX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 243 M
Dividend Yield 0.00%
Description Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Contact 6310 Nancy Ridge Drive, San Diego, CA, 92121 https://www.cidara.com
IPO Date April 15, 2015
Employees 38
Officers Dr. Jeffrey L. Stein Ph.D. President, Chief Executive Officer & Executive Director Mr. Shane M. Ward J.D. Chief Operating Officer & Corporate Secretary Dr. Kevin M. Forrest Ph.D. Founder & Chief Strategy Officer Mr. Jim Beitel M.B.A. Chief Business Officer Dr. Preetam Shah M.B.A., Ph.D. Principal Accounting Officer Ms. Allison Lewis CCP, SPHR Senior Vice President of People & Culture Mr. Frank L. Karbe M.B.A. Chief Financial Officer Dr. Leslie Tari Ph.D. Chief Scientific Officer Dr. Nicole Davarpanah J.D., M.D. Interim Chief Medical Officer and Senior Vice President of Translational Research & Development